Literature DB >> 12453275

Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.

Shih-Pei Huang1, Ming-Shiang Wu, Hsiu-Po Wang, Chang-Shiu Yang, Min-Liang Kuo, Jaw-Town Lin.   

Abstract

BACKGROUND AND AIM: Vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) are associated with the disease status of gastric carcinoma. However, their relationship remains unclear. This study aims to determine and correlate serum levels of VEGF and IL-6 in gastric carcinoma.
METHODS: A total of 107 patients receiving gastrectomy entered this study. Serum levels of VEGF and IL-6 were measured by using ELISA, and were analyzed by using the Student's t-test to compare means and by Pearson correlation analysis to calculate correlation coefficients with respect to pathological characteristics including depth of tumor invasion, Laurén's classification, tumor location, Borrmann classification, and the status of lymph node metastasis.
RESULTS: Serum VEGF levels were significantly higher in patients with mixed type carcinoma (387.5 +/- 176.9 vs 255.3 +/- 154.1 pg/mL, P = 0.047) or lymph node metastasis (339.1 +/- 205.1 vs 223.2 +/- 197.4 pg/mL, P = 0.007). Serum IL-6 levels were significantly higher in patients with Borrmann type IV carcinoma, compared with Borrmann type II and III carcinoma. In general, no correlation was noted between serum VEGF levels and IL-6 levels (r = 0.142, P = 0.145), but significant correlation was found in patients with early gastric carcinoma (r = 0.627, P = 0.004) or mixed type carcinoma (r = 0.804, P = 0.016).
CONCLUSIONS: This study supports the correlation between serum VEGF and IL-6 levels in distinct subsets of gastric carcinoma patients, and indicates that IL-6 may play a role for the angiogenesis of gastric carcinoma via modulation of VEGF. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453275     DOI: 10.1046/j.1440-1746.2002.02873.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  15 in total

1.  Helicobacter pylori outer membrane proteins on gastric mucosal interleukin 6 and 11 expression in Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; David Y Graham; Yoshio Yamaoka
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

2.  Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours.

Authors:  S L Sheng; S H Bao; G Huang; L M Wang
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

3.  Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.

Authors:  Shin-Ae Lee; Seok-Reyol Choi; Jin-Seok Jang; Jong-Hun Lee; Myung-Hwan Roh; Sang Ock Kim; Min-Chan Kim; Su-Jin Kim; Jin-Sook Jeong
Journal:  Dig Dis Sci       Date:  2009-09-12       Impact factor: 3.199

4.  Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells.

Authors:  Mineko Iwai; Masahiko Matsuda; Yoshiaki Iwai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

5.  Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer.

Authors:  A Kominea; P A Konstantinopoulos; N Kapranos; G Vandoros; M Gkermpesi; P Andricopoulos; S Artelaris; S Savva; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-13       Impact factor: 4.553

6.  Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Motoshi Miyagi; Junya Kizaki; Taro Isobe; Kousuke Hashimoto; Kazuo Shirouzu
Journal:  World J Crit Care Med       Date:  2013-11-04

7.  Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mariusz Gryko; Bogusław Kędra; Maciej Szmitkowski
Journal:  Clin Exp Med       Date:  2010-10-12       Impact factor: 3.984

Review 8.  Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis.

Authors:  Ying Huang; Ji-Feng Feng; Jin-Shi Liu; Qi-Xun Chen
Journal:  Ther Clin Risk Manag       Date:  2015-01-21       Impact factor: 2.423

9.  Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer.

Authors:  Do-Kyong Kim; Sung Yong Oh; Hyuk-Chan Kwon; Suee Lee; Kyung A Kwon; Byung Geun Kim; Seong-Geun Kim; Sung-Hyun Kim; Jin Seok Jang; Min Chan Kim; Kyeong Hee Kim; Jin-Yeong Han; Hyo-Jin Kim
Journal:  BMC Cancer       Date:  2009-05-20       Impact factor: 4.430

10.  Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.

Authors:  Hua-chuan Zheng; Xiao-han Li; Takuo Hara; Shinji Masuda; Xiang-hong Yang; Yi-fu Guan; Yasuo Takano
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.